ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Okays Agreement Between Allegheny, Pitt, Over NSABP

February 3, 1995

NIH Updates Policy On Large Grants

May 10, 1996

Three researchers share Paul Marks Prize.

November 11, 2005

Smoking & Health Contractors Meet

July 11, 1975

RFPS, RFAs Available

September 23, 1994

New Concept For Prevention Units Goes to DCPC BSC

April 24, 1987